Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRIFECTO is a veterinary combination drug available in Australia, primarily used for the treatment and control of internal parasites in animals. It contains four active pharmaceutical ingredients—abamectin, levamisole hydrochloride (a derivative of levamisole), oxfendazole, cobalt, and sodium selenite. Abamectin is an avermectin class antiparasitic that acts by binding to glutamate-gated chloride channels in nerve and muscle cells of parasites, causing paralysis and death. Levamisole is an imidazothiazole-class anthelmintic that works as a nicotinic acetylcholine receptor agonist at the neuromuscular junctions of nematodes, leading to paralysis. Oxfendazole is a benzimidazole-class broad-spectrum anthelmintic that inhibits microtubule polymerization by binding to beta-tubulin in parasitic worms. Cobalt and sodium selenite are trace minerals included as nutritional supplements to support animal health[1]. This product appears to be intended for veterinary use only.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TRIFECTO.